

COVID-19 vaccines

Dr. Manish Sadarangani

Director, Vaccine Evaluation Center, BC Children's Hospital Research Institute
Associate Professor, Division of Infectious Diseases, Department of Pediatrics, UBC
Physician Lead, Family Immunization Clinic, BC Children's Hospital

31 March 2021



THE UNIVERSITY
OF BRITISH COLUMBIA
Faculty of Medicine



Vaccine
Evaluation
Center






Disclosures

- Salary awards
 - BC Children's Hospital Foundation
 - Michael Smith Foundation for Health Research
 - Canadian Child Health Clinician Scientist Program
- Research/Project Funding
 - Merck, VBI Vaccines, GlaxoSmithKline, Pfizer, Sanofi-Pasteur, Seqirus, Symvivo
- All funds have been paid to my institute
- Not received any personal payments



COVID-19 vaccine platforms



<https://www.scientificamerican.com/article/genetic-engineering-could-make-a-covid-19-vaccine-in-months-rather-than-years1/>

CDC; Fang et al. Lancet 2020



In Canada

- Agreements announced with

Company	Vaccine type	Clinical phase	Reported efficacy (vs. symptomatic disease)
Pfizer/BioNTech	RNA	Phase 3	95% (2 doses)
Moderna	RNA	Phase 3	95% (2 doses) 92% (1 dose)
Oxford University/Astra Zeneca	Viral vector	Phase 3	65-75% (1 or 2 doses)
Johnson & Johnson	Viral vector	Phase 3	67% (1 dose)
Novavax	Subunit	Phase 3	89% (2 doses) – press release
Medicago	Subunit	Phase 3	Trials ongoing
Sanofi/GlaxoSmithKline	Subunit	Phase 2	Development paused

